SCHEMBL11976565

SCHEMBL11976565

Cc1ccc(-c2cc(-c3ccc(C)cc3)nc(-c3ccc(C)nc3)n2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.47
KMT2A Q03164 4/20 0.47
KDM4E B2RXH2 4/20 0.47
ALDH1A1 P00352 4/20 0.47
MAPT P10636 2/20 0.47
HPGD P15428 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
ADORA3 P0DMS8 6/20 0.44
AGTR1 P30556 1/20 0.44
METAP2 P50579 1/20 0.43
METAP1 P53582 1/20 0.43
ADORA1 P30542 2/20 0.41
EGFR P00533 1/20 0.41
KDR P35968 1/20 0.41
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
SHMT2 P34897 1/20 0.40
PIK3CD O00329 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12628235 0.87 MEN1 (0.53) MEN1KMT2AKDM4EALDH1A1MAPT
SCHEMBL11976544 0.86 HPGDS (0.43) MEN1KMT2AKDM4EALDH1A1MAPT
SCHEMBL15025704 0.85 MEN1 (0.47) MEN1KMT2AKDM4EALDH1A1MAPT
SCHEMBL15025991 0.84 ADORA3 (0.46) MEN1KMT2AKDM4EALDH1A1MAPT
SCHEMBL14804381 0.84 ADORA3 (0.50) MEN1KMT2AKDM4EALDH1A1MAPT
SCHEMBL11976563 0.83 MEN1 (0.49) MEN1KMT2AKDM4EALDH1A1MAPT
SCHEMBL11976557 0.82 MEN1 (0.59) MEN1KMT2AKDM4EALDH1A1MAPT
SCHEMBL15025990 0.81 ADORA3 (0.47) MEN1KMT2AKDM4EALDH1A1MAPT
SCHEMBL19009564 0.81 MEN1 (0.54) MEN1KMT2AKDM4EALDH1A1MAPT
SCHEMBL28791301 0.80 HPGDS (0.44) MEN1KMT2AALDH1A1MAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9048442-B2 Composition containing a metal complex and organic compound, and light-emitting element using said compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2015-06-02 US disclosed
US-9048442-B2 Composition containing a metal complex and organic compound, and light-emitting element using said compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2015-06-02 US disclosed
EP-2492276-B1 METAL COMPLEX, POLYMER, AND ELEMENT OBTAINED USING SAME SUMITOMO CHEMICAL CO (JP) 2014-10-08 EP disclosed
US-20120205585-A1 METAL COMPLEX, POLYMER COMPOUND AND DEVICE USING THE SAME SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-08-16 US disclosed
US-20110114890-A1 COMPOSITION CONTAINING A METAL COMPLEX AND ORGANIC COMPOUND, AND LIGHT-EMITTING ELEMENT USING SAID COMPOUND SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-05-19 US disclosed
US-20110114890-A1 COMPOSITION CONTAINING A METAL COMPLEX AND ORGANIC COMPOUND, AND LIGHT-EMITTING ELEMENT USING SAID COMPOUND SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-05-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120205585-A1 METAL COMPLEX, POLYMER COMPOUND AND DEVICE USING THE SAME HDAC10, EMG1, PRMT1 MEN1 484/4885KMT2A 420/4885KDM4E 1254/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.